Synchron Pauses Clinical Trials for Second-Generation Brain Implant
Performance issues with the device's lead cable force a strategic hardware redesign.
1Clinical Trial Enrollment Halted
Synchron has voluntarily paused enrollment for its second-generation brain-computer interface trials after identifying performance issues. The company confirmed that the lead cable, which transmits signals from the implanted Stentrode to internal electronics, failed to meet expected standards. This decision was made internally by the firm rather than being mandated by the FDA.
2Minimally Invasive Stentrode Technology
Unlike competitors requiring brain surgery, Synchron’s Stentrode is inserted via the jugular vein to rest on the motor cortex. The first-generation device allowed ten volunteers to control digital tools like email and banking through thought. The new iteration aims to improve this functionality by moving to a fully wireless, Bluetooth-connected system design.
3Internalizing Design and Manufacturing
In response to the technical failure, Synchron is shifting its lead design and manufacturing processes in-house. The company is currently scaling back its New York operations while aggressively building a new engineering team in San Diego. This facility will focus on upgrading the entire Stentrode system to ensure future trial success.
4Safety Status and Participant Care
Synchron emphasized that the performance issue is not related to the Stentrode itself and poses no safety risks to trial participants. The company remains committed to supporting existing volunteers throughout their lifetimes. Recruitment at US trial sites is currently suspended while the hardware undergoes necessary upgrades to meet the required signal readouts.
5Strategic Shift to San Diego
The new San Diego team is tasked with developing the upgraded lead and a secret, future device that operates beyond blood vessels. CEO Tom Oxley noted that this upcoming technology aims to reach multiple brain regions simultaneously. This expansion could enable more complex, natural functions beyond simple cursor movements or basic mouse clicks.
6Competitive Landscape and Valuation
Synchron, valued at nearly $1 billion after a $200 million funding round, competes directly with Elon Musk’s Neuralink. Neuralink, valued at approximately $42 billion, faced its own challenges in 2024 when implant wires retracted in a volunteer. Both companies are navigating the high-stakes, experimental nature of developing brain-computer interfaces for human use.
7AI Integration in Neurotechnology
Advancements in artificial intelligence are accelerating the development of brain-computer interfaces by enabling faster, more accurate signal processing. Companies like Merge Labs, co-founded by Sam Altman, are already collaborating with AI developers to refine these patterns. These models are essential for translating complex neural activity into precise output commands for users.
8Path Toward Commercial Approval
Synchron’s current trials are critical for advancing toward a pivotal study required for FDA marketing approval. While the setback highlights the experimental status of these devices, the company maintains strong confidence in the Stentrode’s potential as a first-line therapy. Future progress depends on successfully completing hardware upgrades and resuming clinical enrollment.